Biological Activity

Bioactivity / Mechanism

Bethanechol chloride acted as a muscarinic agonist that preferentially engaged an M2-associated, membrane-delimited calcium-channel signaling pathway in neonatal rat sympathetic neurons. Antagonist and voltage-prepulse controls supported this interpretation. This functional selectivity is specific to the tested preparation and does not establish universal M2 receptor selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target	Activity	Value
mAChR

In Vitro Studies

In neonatal rat superior cervical ganglion neurons, bethanechol chloride inhibited whole-cell peak current with a fitted functional IC50 of 8.2 μM. This value describes current inhibition under the recording conditions, rather than binding affinity. At 100 μM it reduced peak current while largely sparing the L-type long-lasting tail current; most inhibition was relieved by a depolarizing prepulse. [1]

Functional concentration–response in neonatal sympathetic neurons

Cell-based study · Acutely dissociated superior cervical ganglion neurons from 1–3-day-old Sprague–Dawley rats; whole-cell voltage clamp with Ba2+ as charge carrier. [1]

Bethanechol inhibited peak current concentration-dependently. Most inhibition was lost after pertussis-toxin pathway blockade. The fitted IC50 describes this electrophysiological assay, not receptor binding affinity.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Peak-current inhibition in untreated neurons	Functional IC50 8.2 μM	[1]
Maximum peak-current inhibition at 30 μM bethanechol	Mean ± SEM inhibition Untreated: 44 ± 3%; pathway-blocked: 11 ± 3%	[1]

Literature-Reported Treatment Conditions

Treatment concentration: 0.01–3000 μM
Exposure duration: Current measured after 2 min of superfusion or on reaching steady state.
Method: Superfusion; +10 mV test potential; pipette BAPTA 0.1 mM.
Vehicle: Aqueous stock diluted into external recording solution.
Co-treatment: Parallel untreated and pertussis-toxin-pretreated cells; oxotremorine-M comparator.
Reported limits: No lot, purity or stereochemical specification reported in the retrieved material.

Methods and source locations

Compound reported in the paper: Bethanechol chloride; Compound label in the paper: BeCh

Evidence for the named compound in the reported preparation; no Adooq lot validation or salt conversion.

Figure 6b,d and caption; Results: concentration-dependent peak-current inhibition; Methods: Current recordings, Drugs and solutions

Peak-current inhibition in untreated neurons: Sigmoidal nonlinear regression; 3–9 recordings per data point; no uncertainty interval printed for IC50. — Figure 6b, printed fitted-curve annotation; caption

Maximum peak-current inhibition at 30 μM bethanechol: Whole-cell current; 3–9 recordings per concentration in Figure 6; higher concentrations did not significantly increase inhibition. — Results paragraph preceding Figure 6; Figure 6b,d

Model-specific muscarinic pathway validation

Cell-based study · Neonatal rat superior cervical ganglion neurons; whole-cell Ba2+ currents through voltage-gated calcium channels. [1]

At 100 μM, bethanechol reversibly inhibited predominantly N-type peak current with little effect on the L-type long-lasting tail current. Positive prepulses relieved inhibition. Antagonist controls support an M2-mediated membrane-delimited pathway in this neonatal neuronal preparation.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Peak and long-lasting tail current responses	Mean ± SEM peak inhibition 38.2 ± 5.7% (n = 3 recordings); no obvious tail-current inhibition	[1]
Relief of bethanechol inhibition by depolarizing prepulse	Mean ± SEM inhibition Without prepulse: 31 ± 7%; after prepulse: 5 ± 4% (P > 0.05 vs corresponding control)	[1]
Bethanechol inhibition after M1 blockade, with additional antagonists	Mean ± SEM inhibition No additional antagonist: 41 ± 6%; pirenzepine: 37 ± 7%; pirenzepine + methoctramine: −4 ± 3%; methoctramine: −15 ± 3%	[1]

Literature-Reported Treatment Conditions

Treatment concentration: Bethanechol 100 μM; methoctramine and pirenzepine each 100 nM where tested.
Exposure duration: Acute superfusion; a single fixed exposure duration is not specified for all validation panels.
Method: Whole-cell electrophysiology with low pipette BAPTA (0.1 mM); FPL 64176 used to distinguish L-type tail current.
Vehicle: Aqueous bethanechol stock diluted into recording solution.
Co-treatment: Muscarinic receptor antagonist controls, pathway-blocked cells, prepulse comparison and oxotremorine-M positive comparator.
Reported limits: These experiments do not determine universal subtype selectivity or direct channel binding.

Methods and source locations

Compound reported in the paper: Bethanechol chloride; Compound label in the paper: BeCh

Evidence for the named compound in the reported preparation; no Adooq lot validation or salt conversion.

Figures 3c,d, 5a–e and 7; accompanying Results; shared recording methods

Peak and long-lasting tail current responses: Bethanechol 100 μM in FPL-containing bath; paired control recordings. Tail-current result retained qualitatively. — Figure 5a,b,e and caption

Relief of bethanechol inhibition by depolarizing prepulse: Two-tailed paired t-tests; caption specifies n = 8–9 recordings/group across Figure 3. — Figure 3c,d and caption

Bethanechol inhibition after M1 blockade, with additional antagonists: Figure 7 reports n = 6–7 recordings/group; both methoctramine-containing conditions P > 0.05. Negative inhibition values mean small nonsignificant current increases. — Figure 7 and caption; Results receptor-antagonist paragraphs

In Vivo Studies

In an azoxymethane-induced mouse colon neoplasia model, 20 weeks of bethanechol chloride in drinking water was associated with higher reported tumor counts and greater Ki67 labeling in normal epithelium and adenocarcinomas than AOM alone. Apoptosis and adenoma counts were not significantly changed according to the paper. These findings concern a carcinogen-exposed animal model and do not establish the effect of bethanechol alone. [2]

The direction differed in a hamster pancreatic carcinogenesis study: single bethanechol chloride exposure around BOP administration was associated with lower reported pancreatic carcinoma incidence. Benign lesions did not uniformly decrease, and the mechanism remained unresolved. Daily dosing caused substantial mortality, including in bethanechol-only animals, and was stopped early. These results do not support a general antitumor or tolerability claim. [3]

Colon neoplasia during chronic bethanechol exposure

Animal study · Male WT 129S6/SvEv × CF1 mice in an azoxymethane-induced colon neoplasia model; N = 8 control and 7 bethanechol-treated mice. [2]

Bethanechol-exposed mice had higher reported tumor counts and Ki67 labeling in normal epithelium and adenocarcinomas than the AOM-only controls. Apoptosis and adenoma counts were not significantly altered according to the paper. These are outcomes under concurrent carcinogen exposure, not bethanechol-alone carcinogenicity or an antitumor effect.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Colon tumors per mouse at week 20	Mean ± SE Bethanechol + AOM: 10.4 ± 1.5; AOM control: 8.0 ± 1.3	[2]
Ki67-positive cells in normal epithelium and adenocarcinomas	Mean ± SE (%) Normal: 44.4 ± 3.5 vs 38.3 ± 1.6; adenocarcinoma: 50.2 ± 1.4 vs 43.2 ± 1.8 (bethanechol vs control)	[2]
Adenoma counts, adenoma Ki67 labeling and cleaved-caspase-3 labeling	Reported negative comparisons No statistically significant change reported for adenoma count, adenoma Ki67 labeling, or cleaved-caspase-3 labeling in normal mucosa, adenomas or adenocarcinomas.	[2]

Conditions shared by the study groups

Route: Oral, ad libitum drinking water
Frequency: Continuous access
Treatment course: 20 weeks; animals euthanized at week 20
Vehicle: Drinking water

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Bethanechol in AOM model 400 μg/mL in drinking water	Water without bethanechol; both groups received weekly AOM 10 mg/kg i.p. during the initial 6 weeks.	Higher descriptive tumor counts and Ki67 labeling in selected compartments; apoptosis was not significantly changed according to the paper.	[2]

Bethanechol in AOM model: Model: Male WT 129S6/SvEv × CF1 mice; 7 treated versus 8 controls; Reported limits: Individual systemic exposure not measured; no bethanechol-only group in this experiment.

Methods and source locations

Compound reported in the paper: Bethanechol chloride; Compound label in the paper: Bethanechol

Evidence for the named compound in the reported preparation; no Adooq lot validation or salt conversion.

Methods: Materials, Animals, treatment, tumor/histological and immunohistological analysis; Results: tumor formation and proliferation; Figures 1–2

Colon tumors per mouse at week 20: Visual identification, tumor measurements and treatment-masked histological adjudication; N = 7 and 8, respectively. Descriptive means retained; no inferential P value adopted. — Results: Bethanechol promotes colon tumor formation; Figure 1C and caption

Ki67-positive cells in normal epithelium and adenocarcinomas: Immunohistology quantified by ImageScope; Figure 2 specifies N = 7 treated, 8 control mice. Readouts belong to the same animal cohort, not separate cellular studies. — Results: Bethanechol stimulates cell proliferation; Figure 2B and caption

Adenoma counts, adenoma Ki67 labeling and cleaved-caspase-3 labeling: Same cohort; qualitative retention of negative results. No new numeric values inferred from bars. — Figure 1C; Figure 2B,D; associated captions and Results

Bethanechol in AOM model · Methods: Bethanechol and azoxymethane treatment; Figures 1–2 captions

Single-exposure modification of hamster pancreatic carcinogenesis

Animal study · Outbred male and female Syrian golden hamsters; chemically induced pancreatic neoplasia after BOP. [3]

Single-dose bethanechol schedules were associated with lower reported pancreatic carcinoma incidence than BOP alone. The selected quantitative comparison is pretreatment 120 min before BOP. Benign lesions did not show a uniform protective pattern, and simultaneous treatment produced larger adenomas. The paper leaves the inhibitory mechanism unresolved.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Pancreatic carcinoma incidence including carcinoma in situ, females and males combined	Reported incidence (%) BC 120 min before BOP (Group 1): 1 (2.6%); BOP only (Group 6): 21 (52.5%)	[3]
Ductular proliferation and benign adenoma pattern	Qualitative limiting result No uniform reduction in benign lesions; the simultaneous BOP + BC group had larger adenomas than BOP controls.	[3]

Conditions shared by the study groups

Route: Subcutaneous
Frequency: Once
Treatment course: 120 min before single BOP administration; surviving animals killed 46 weeks after BOP
Vehicle: Physiologic saline

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
BC 120 min before BOP (Group 1) 15 mg/kg body weight	BOP-only Group 6; BOP 20 mg/kg subcutaneously. BC-only and saline control groups were also included in the paper.	Reported all-time pancreatic carcinoma incidence was lower than BOP alone; mechanisms remain uncertain.	[3]

BC 120 min before BOP (Group 1): Model: Outbred Syrian golden hamsters of both sexes; Reported limits: Table 1 examined counts differ from the initial planned group sizes. This record uses the table-specific examined population, not an invented randomized denominator.

Methods and source locations

Compound reported in the paper: Bethanechol chloride; Compound label in the paper: BC

Evidence for the named compound in the reported preparation; no Adooq lot validation or salt conversion.

Printed pp. 179–184, especially Materials and Methods, Table 1, Table 2 total-carcinoma row, Table 3 and Discussion

Pancreatic carcinoma incidence including carcinoma in situ, females and males combined: Table 2 total row; percentages refer to the examined populations in Table 1 (20 female + 19 male in Group 1; 20 + 20 in Group 6). Includes animals examined before terminal sacrifice; do not substitute terminal survivors as denominators. — Table 2, p. 182: Total carcinomas, Groups 1 and 6; Table 1 p. 180

Ductular proliferation and benign adenoma pattern: Distinct timing groups within the single-exposure comparison; no general pancreatic tumor-prevention claim. — Results and Discussion p. 181; Table 2 p. 182

BC 120 min before BOP (Group 1) · Materials and Methods p. 179; Table 1 p. 180; Table 2 p. 182

High mortality during repeated bethanechol administration

Animal study · Outbred Syrian golden hamsters of both sexes; repeated BC after BOP (Group 3) and repeated BC alone (Group 7). [3]

Daily bethanechol was discontinued at week 24 because of high mortality. The BOP + daily-BC and daily-BC-only groups had poor survival, limiting interpretation of their tumor outcomes. The authors considered the chronic group inadequate for firm statistical conclusions about greater cancer inhibition.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Survival until week 46	Reported survival (%) BOP + daily BC (Group 3): 12%; daily BC alone (Group 7): 19%; BOP-only (Group 6): 88%; saline control (Group 8): 58%	[3]

Conditions shared by the study groups

Route: Subcutaneous
Frequency: Daily
Treatment course: Stopped at 24 weeks because of high mortality; remaining animals followed to 46 weeks after BOP
Vehicle: Physiologic saline

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Daily BC following BOP and BC-only control 7.5 mg/kg body weight	BOP-only and physiologic-saline controls; daily BC-alone group distinguishes mortality without BOP.	High mortality occurred with daily BC both with and without BOP; reduced tumor incidence in the chronic group cannot establish a well-tolerated benefit.	[3]

Daily BC following BOP and BC-only control: Model: Syrian golden hamsters, females and males; Reported limits: Initial allocation, the examined histology populations and survival denominators are not fully reconciled in the paper; percentages remain the reported Table 1 values.

Methods and source locations

Compound reported in the paper: Bethanechol chloride; Compound label in the paper: BC

Evidence for the named compound in the reported preparation; no Adooq lot validation or salt conversion.

Materials and Methods and Results p. 179; Table 1 p. 180; Discussion pp. 181, 183

Survival until week 46: Table 1 survival column and Results p. 179; percentages retained as reported. The paper does not fully reconcile initial allocation, the examined histology populations and survival denominators; no new survival fraction is calculated. — Table 1 p. 180; Results p. 179

Daily BC following BOP and BC-only control · Materials and Methods p. 179; Table 1 p. 180

Specifications

Manufacturer	Adooq Bioscience
Actions	Agonist
CAS Number	590-63-6
Applications	Muscarinic receptor agonist
Formula	C₇H₁₇N₂O₂.Cl
Molecular Weight	196.68
SMILES	CC(C[N+](C)(C)C)OC(=O)N.[Cl-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

Solvent	Reported Solubility
DMSO	34 mg/mL (172.87 mM)
Water	34 mg/mL (172.87 mM)
Ethanol	34 mg/mL (172.87 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] Liwang Liu, Ann R Rittenhouse. Pharmacological discrimination between muscarinic receptor signal transduction cascades with bethanechol chloride British Journal of Pharmacology (2003). PMID: 12711626 DOI: 10.1038/sj.bjp.0705157 Source material
[2] Zhongsheng Peng, Jonathon Heath, Cinthia Drachenberg, et al. Cholinergic muscarinic receptor activation augments murine intestinal epithelial cell proliferation and tumorigenesis BMC Cancer (2013). PMID: 23617763 DOI: 10.1186/1471-2407-13-204 Source material
[3] Parviz M Pour, Thorkatla Donnelly, Katherine Stepan. Modification of pancreatic carcinogenesis in the hamster model. 7. Inhibitory effect of bethanechol chloride. American Journal of Pathology (1983). PMID: 6136184 Source material

Documents & Downloads

Bethanechol chloride

Select a Size

Package Sizes

DMSO Solution